Kevin Barton
YOU?
Author Swipe
View article: INNV-11. Single institution retrospective study determining characteristics of non-enhancing glioblastoma
INNV-11. Single institution retrospective study determining characteristics of non-enhancing glioblastoma Open
BACKGROUND Glioblastomas are contrast enhancing tumors with perilesional edema. On the other hand, IDH mutant/low grade gliomas are non-contrast enhancing tumors. A small percentage of glioblastomas present as non-enhancing lesions. Molecu…
View article: BIOM-102. LAROTRECTINIB FOR NTRK AMPLIFICATION IN GLIOBLASTOMA: CASE REPORT
BIOM-102. LAROTRECTINIB FOR NTRK AMPLIFICATION IN GLIOBLASTOMA: CASE REPORT Open
We report a case of a 51-year-old man with left hemispheric multifocal, O6-methylguanine-DNA methyltransferase (MGMT) unmethylated glioblastoma with neurotrophic tyrosine receptor kinase 2 (NTRK2) amplification. He underwent complete resec…
View article: NCOG-13. Single institution retrospective analysis of survival of patients with MGMT unmethylated glioblastoma (IDH-wt) at a comprehensive neuro-oncology center
NCOG-13. Single institution retrospective analysis of survival of patients with MGMT unmethylated glioblastoma (IDH-wt) at a comprehensive neuro-oncology center Open
INTRODUCTION National statistics estimate the median survival of patients with O6-methylguanine-DNA methyltransferase (MGMT) unmethylated glioblastomas to be approximately 12 months. However, institutions with multidisciplinary neuro-oncol…
View article: TGFβ-activated kinase-1 knockdown in hematopoietic stem-progenitor cells causes PANoptosis and myelodysplastic syndrome-like disease in mice
TGFβ-activated kinase-1 knockdown in hematopoietic stem-progenitor cells causes PANoptosis and myelodysplastic syndrome-like disease in mice Open
Mutant SF3B1 (SF3B1mut) in hematopoietic stem/progenitor cells (HSPCs) primarily affects erythropoiesis, resulting in myelodysplastic syndromes (MDS) with refractory macrocytic anemia and ring sideroblasts. SF3B1mut results in aberrant spl…
View article: Role of nuclear receptors, lipid metabolism, and mitochondrial function in the pathogenesis of diabetic kidney disease
Role of nuclear receptors, lipid metabolism, and mitochondrial function in the pathogenesis of diabetic kidney disease Open
Diabetic kidney disease (DKD) is a leading cause of end-stage renal disease (ESRD) and remains a significant clinical challenge due to its complex pathogenesis. This review explores the intricate interplay of metabolic, inflammatory, and c…
View article: The non-steroidal MR antagonist Finerenone reverses Western diet-induced kidney disease by regulating mitochondrial and lipid metabolism and inflammation
The non-steroidal MR antagonist Finerenone reverses Western diet-induced kidney disease by regulating mitochondrial and lipid metabolism and inflammation Open
Mineralocorticoid receptor (MR) overactivation plays a crucial role in the pathogenesis of chronic kidney disease, as well as several cardiovascular and arterial diseases. Current studies determined the mechanisms of the beneficial kidney …
View article: INNV-04. SINGLE INSTITUTION RETROSPECTIVE STUDY TO DETERMINE TIME TO FIRST PROGRESSION IN MGMT METHYLATED GLIOBLASTOMA PATIENTS WHO RECEIVED STANDARD OF CARE
INNV-04. SINGLE INSTITUTION RETROSPECTIVE STUDY TO DETERMINE TIME TO FIRST PROGRESSION IN MGMT METHYLATED GLIOBLASTOMA PATIENTS WHO RECEIVED STANDARD OF CARE Open
MGMT methylated glioblastomas respond well to standard of care with temozolomide, have a longer survival as well as increased risk of pseudo-progression as compared to unmethylated patients. Shorter survival in these patients despite effec…
View article: Caspase 8 deletion causes infection/inflammation-induced bone marrow failure and MDS-like disease in mice
Caspase 8 deletion causes infection/inflammation-induced bone marrow failure and MDS-like disease in mice Open
Myelodysplastic syndromes (MDS) are a heterogeneous group of pre-leukemic hematopoietic disorders characterized by cytopenia in peripheral blood due to ineffective hematopoiesis and normo- or hypercellularity and morphologic dysplasia in b…
View article: Age-stratified comorbid and pharmacologic analysis of patients with glioblastoma
Age-stratified comorbid and pharmacologic analysis of patients with glioblastoma Open
Age-dependent novel associations between clinical symptoms and medications prescribed for co-morbid conditions were demonstrated in patients with GBM. The results of the current work support future mechanistic studies that investigate the …
View article: PATH-04. TRANSFORMATION OF GRADE 2 OLIGODENDROGLIOMA TO GLIOSARCOMA WITH RAPID AND EXTENSIVE PROGRESSION: CASE REPORT.
PATH-04. TRANSFORMATION OF GRADE 2 OLIGODENDROGLIOMA TO GLIOSARCOMA WITH RAPID AND EXTENSIVE PROGRESSION: CASE REPORT. Open
Transition of WHO grade 2 oligodendroglioma to gliosarcoma is rare. We report a case of a 40 year-old gentleman with WHO grade 2 oligodendroglioma, isocitrate dehydrogenase enzyme (IDH)-mutant, 1p/19q co-deletion positive, O6-methylguanine…
View article: CNSC-20. MGMT PROMOTER METHYLATED HIGH GRADE GLIOMA WITH DISTANT RECURRENCE AND STABLE ORIGINAL TUMOR SITE: CASE SERIES
CNSC-20. MGMT PROMOTER METHYLATED HIGH GRADE GLIOMA WITH DISTANT RECURRENCE AND STABLE ORIGINAL TUMOR SITE: CASE SERIES Open
Recurrence pattern in high grade glioma is classified as local and distant recurrence based on distance from original resection cavity and radiation field. We report the first series of three cases of O6-methylguanine-DNA methyltransferase…
View article: IMMU-27. NON-TUMOR CELL IDO1 NON-ENZYMATICALLY DECREASES RT + PD-1 MAB TREATMENT EFFICACY IN OLDER ADULTS WITH GLIOBLASTOMA
IMMU-27. NON-TUMOR CELL IDO1 NON-ENZYMATICALLY DECREASES RT + PD-1 MAB TREATMENT EFFICACY IN OLDER ADULTS WITH GLIOBLASTOMA Open
Checkmate 498 is a large, randomized, phase 3 clinical trial that demonstrated an improved hazard ratio for younger but not older adults with MGMT unmethylated GBM treated with RT + PD-1 mAb. In an effort to better understand the biologica…
View article: CSIG-33. A 2ND GENERATION IDO1 PROTEIN DEGRADER TO OVERCOME NON-ENZYME-MEDIATED IDO1-DEPENDENT IMMUNE SUPPRESSION FOR GLIOBLASTOMA
CSIG-33. A 2ND GENERATION IDO1 PROTEIN DEGRADER TO OVERCOME NON-ENZYME-MEDIATED IDO1-DEPENDENT IMMUNE SUPPRESSION FOR GLIOBLASTOMA Open
Indoleamine 2,3-dioxygenase 1 (IDO1) is an immunosuppressive rate-limiting enzyme that metabolizes the essential amino acid, tryptophan (Trp), into the downstream catabolite, kynurenine. IDO1 is expressed in >90% of patient-resected gli…
View article: EXTH-41. COMBINATION TREATMENT OF CALCIUM CHANNEL ANTAGONIST MIBEFRADIL ENHANCES THE EFFECT OF HYDROXYUREA AT THERAPEUTIC RANGES IN HIGH-GRADE MENINGIOMA <i>IN VITRO</i>
EXTH-41. COMBINATION TREATMENT OF CALCIUM CHANNEL ANTAGONIST MIBEFRADIL ENHANCES THE EFFECT OF HYDROXYUREA AT THERAPEUTIC RANGES IN HIGH-GRADE MENINGIOMA <i>IN VITRO</i> Open
High-grade meningiomas (MNs), WHO Grade II- III, are highly aggressive brain tumors that are difficult to treat. Standard chemotherapy agents are, at best, moderately effective in treating high-grade MNs. There is great interest in develop…
View article: MGMT Methylated High Grade Glioma with Distant Recurrence and Stable Original Tumor Site: Case Series
MGMT Methylated High Grade Glioma with Distant Recurrence and Stable Original Tumor Site: Case Series Open
We present three cases of O6-Methylguanine-DNA Methyltransferase (MGMT) methylated high grade gliomas with distant recurrence. All three patients had a radiographic stability of original tumor site at time of distant recurrence indicating …
View article: Continuation of Temozolomide Chemotherapy in a Glioblastoma Patient Post Resolution of COVID-19 Pneumonia
Continuation of Temozolomide Chemotherapy in a Glioblastoma Patient Post Resolution of COVID-19 Pneumonia Open
Case ReportWe present a case of a previously healthy 33 years old patient who presented with severe headaches and was found to have a right parietal lobe heterogeneously enhancing intra-axial neoplasm on magnetic resonance imaging (MRI) of…
View article: <scp>COVID</scp>‐19 thromboembolism incidence, risk factors, and anticoagulation practices from a Chicago metropolitan <scp>US</scp> population
<span>COVID</span>‐19 thromboembolism incidence, risk factors, and anticoagulation practices from a Chicago metropolitan <span>US</span> population Open
Coronavirus 2019 (COVID-19), caused by the novel severe acute respiratory (SARS) coronavirus 2 (CoV-2), has infected millions worldwide. Abnormal coagulation parameters are often present in COVID-19-hospitalized patients, which may increas…
View article: Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma
Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma Open
The efficacy of autologous stem-cell transplantation during the first remission in patients with diffuse, aggressive non-Hodgkin's lymphoma classified as high-intermediate risk or high risk on the International Prognostic Index remains con…
View article: Real World Outcomes of Sars-Cov-2 Thrombosis Rates across Three University Health Systems in the Chicago Metropolitan Area
Real World Outcomes of Sars-Cov-2 Thrombosis Rates across Three University Health Systems in the Chicago Metropolitan Area Open
Introduction: Initial studies from Wuhan, China reported patients infected with SARS-CoV-2 have uncontrolled coagulopathy and an increased risk for thrombotic complications, including pulmonary embolism (PE), deep vein thrombosis (DVT), an…
View article: COVD-29. CONTINUATION OF TEMOZOLOMIDE CHEMOTHERAPY IN A GLIOBLASTOMA PATIENT AFTER RESOLUTION OF COVID-19 PNEUMONIA
COVD-29. CONTINUATION OF TEMOZOLOMIDE CHEMOTHERAPY IN A GLIOBLASTOMA PATIENT AFTER RESOLUTION OF COVID-19 PNEUMONIA Open
We present a case of a 33 year-old patient with glioblastoma (IDH wild type, MGMT unmethylated) who was diagnosed with COVID-19 pneumonia while undergoing chemotherapy. The patient did not have any medical comorbidities. He was clinically …
View article: Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis
Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis Open
Phase II data suggest a benefit to autotransplantation for aggressive T-cell non-Hodgkin lymphoma (T-NHL) in first remission; randomized trials have yet to validate this. We performed a retrospective analysis of aggressive T-NHL patients i…
View article: Value of Ki-67 Labeling Index in Predicting Recurrence of WHO Grade I Cranial Base Meningiomas
Value of Ki-67 Labeling Index in Predicting Recurrence of WHO Grade I Cranial Base Meningiomas Open
Objectives Assess impact of Ki-67 labeling index (LI; Ki-67 LI) on risk of recurrence or progression of WHO grade I meningiomas. Study Design Retrospective study of adult patients who underwent resection of cranial base meningioma between …